SF3B1mut often undergoes aberrant activation of the DNA damage response due to mis‐spliced proteins, thus existing DNA damaging agents (e.g., etoposide) or synthetic lethal small molecule inhibitors (e.g., PARP inhibitors) could preferentially target tumor cells carrying SF3B1 mutation.45, 155. The gene discussed is PARP1; the disease is neoplasm.